Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-02-18 Sale | 2025-02-20 4:15 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 13,313 | $2.43 | $32,351 | 144,316 (Direct) | View |
| 2025-02-03 Sale | 2025-02-05 4:16 pm | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 6,404 | $1.71 | $10,951 | 587,848 (Direct) | View |
| 2025-02-03 Sale | 2025-02-05 4:15 pm | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 4,361 | $1.73 | $7,545 | 1,301,540 (Direct) | View |
| 2025-02-03 Sale | 2025-02-05 4:14 pm | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 14,746 | $1.71 | $25,216 | 250,713 (Direct) | View |
| 2025-02-03 Sale | 2025-02-05 4:13 pm | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 46,003 | $1.68 | $77,285 | 8,230,433 (Indirect Direct) | View |
| 2025-02-03 Sale | 2025-02-05 4:12 pm | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 18,832 | $1.7 | $32,014 | 643,135 (Direct) | View |
| 2025-01-21 Sale | 2025-01-23 4:30 pm | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 27,199 | $1.78 | $48,414 | 488,054 (Direct) | View |
| 2024-12-09 Sale | 2024-12-10 4:53 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 9,136 | $2.18 | $19,916 | 157,629 (Direct) | View |
| 2024-12-05 Sale | 2024-12-09 4:05 pm | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 9,221 | $2.16 | $19,917 | 307,507 (Direct) | View |
| 2024-06-18 Sale | 2024-06-20 4:31 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 18,641 | $2.2793 | $42,488 | 166,765 (Direct) | View |
| 2024-05-30 Sale | 2024-06-03 4:09 pm | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 11,200 | $2.3376 | $26,181 | 255,253 (Direct) | View |
| 2024-05-16 Purchase | 2024-05-20 9:33 pm | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 1,724,137 | $2.9 | $4,999,997 | 10,099,279 (Indirect Direct) | View |
| 2024-01-30 Purchase | 2024-03-06 9:52 pm | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 190 | $3.595 | $683 | 819,590 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-03-01 Option Award | 2025-03-05 4:11 pm | N/A 2035-03-01 | Allogene Therapeutics Inc. | ALLO | Beneski Benjamin Machinas SVP, Chief Technical Officer | 144,094 | $0 | 336,334 (Direct) | View |
Ownership | 2025-03-04 9:58 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Beneski Benjamin Machinas SVP, Chief Technical Officer | 0 | $0 | 323,694 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:16 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 657,298 | $0 | 1,106,622 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:15 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 788,757 | $0 | 1,920,745 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:14 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Yoshiyama Annie SVP, Finance | 164,325 | $0 | 266,083 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:13 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 788,757 | $0 | 1,276,811 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:11 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 1,677,884 | $0 | 12,317,030 (Direct) | View |
| 2025-01-24 Option Award | 2025-01-28 8:10 pm | N/A 2035-01-24 | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 2,504,304 | $0 | 10,228,566 (Direct) | View |
| 2024-10-21 Tax Withholding | 2024-10-23 4:21 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 36,404 | $2.84 | 1,131,988 (Direct) | View |
| 2024-08-21 Tax Withholding | 2024-08-23 4:15 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 28,310 | $2.785 | 449,324 (Direct) | View |
Ownership | 2024-06-11 4:10 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Yoshiyama Annie SVP, Finance | 0 | $0 | 450,466 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:35 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:34 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:33 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director | 157,016 | $0 | 258,116 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:30 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 157,016 | $0 | 412,269 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:29 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:28 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:25 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 122,950 | $0 | 185,406 (Direct) | View |
| 2024-05-16 Option Award | 2024-05-20 9:33 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 344,828 | $2.9 | 10,099,279 (Indirect) | View |
| 2024-05-16 Option Award | 2024-05-20 6:02 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 344,828 | $2.9 | 1,164,418 (Direct) | View |
| 2024-05-16 Option Award | 2024-05-20 6:01 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 344,828 | $2.9 | 7,723,302 (Direct) | View |
| 2024-04-22 Tax Withholding | 2024-04-24 4:18 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 17,360 | $3.4671 | 265,459 (Direct) | View |
| 2024-03-14 Tax Withholding | 2024-03-18 8:10 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 53,393 | $4.33 | 7,378,474 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:51 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 438,115 | $0 | 624,334 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:48 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 189,578 | $0 | 625,412 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:47 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 133,339 | $0 | 923,339 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:46 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 961,371 | $0 | 9,319,579 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:45 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 634,949 | $0 | 1,010,202 (Direct) | View |